Corvus Pharmaceuticals, Inc.
PHARMACEUTICAL FORMULATIONS
Last updated:
Abstract:
The disclosure provides, inter alia, compositions, oral formulations, amorphous solid dispersions, extrudates, crystalline nanoparticles, and microprecipitated bulk powders containing adenosine A2A receptor antagonists, and methods of using the compositions, oral formulations, amorphous solid dispersions, extrudates, crystalline nanoparticles, and microprecipitated bulk powder to treat cancer.
Status:
Application
Type:
Utility
Filling date:
1 Feb 2019
Issue date:
1 Aug 2019